On the other hand, in the phase II of our study, the inclusion criteria did not allow enrollment of EGFR-mutated patients; all subjects were EGFR wild type, and 4 subjects with squamous cell carcinoma were enrolled. The gene discussed is EGFR; the disease is squamous cell carcinoma.